UBE2S interacting with TRIM21 mediates the K11-linked ubiquitination of LPP to promote the lymphatic metastasis of bladder cancer.
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
08 07 2023
08 07 2023
Historique:
received:
18
01
2023
accepted:
30
06
2023
medline:
10
7
2023
pubmed:
9
7
2023
entrez:
8
7
2023
Statut:
epublish
Résumé
Lymphatic metastasis is the most common pattern of bladder cancer (BCa) metastasis and has an extremely poor prognosis. Emerging evidence shows that ubiquitination plays crucial roles in various processes of tumors, including tumorigenesis and progression. However, the molecular mechanisms underlying the roles of ubiquitination in the lymphatic metastasis of BCa are largely unknown. In the present study, through bioinformatics analysis and validation in tissue samples, we found that the ubiquitin-conjugating E2 enzyme UBE2S was positively correlated with the lymphatic metastasis status, high tumor stage, histological grade, and poor prognosis of BCa patients. Functional assays showed that UBE2S promoted BCa cell migration and invasion in vitro, as well as lymphatic metastasis in vivo. Mechanistically, UBE2S interacted with tripartite motif containing 21 (TRIM21) and jointly induced the ubiquitination of lipoma preferred partner (LPP) via K11-linked polyubiquitination but not K48- or K63-linked polyubiquitination. Moreover, LPP silencing rescued the anti-metastatic phenotypes and inhibited the epithelial-mesenchymal transition of BCa cells after UBE2S knockdown. Finally, targeting UBE2S with cephalomannine distinctly inhibited the progression of BCa in cell lines and human BCa-derived organoids in vitro, as well as in a lymphatic metastasis model in vivo, without significant toxicity. In conclusion, our study reveals that UBE2S, by interacting with TRIM21, degrades LPP through K11-linked ubiquitination to promote the lymphatic metastasis of BCa, suggesting that UBE2S represents a potent and promising therapeutic target for metastatic BCa.
Identifiants
pubmed: 37422473
doi: 10.1038/s41419-023-05938-2
pii: 10.1038/s41419-023-05938-2
pmc: PMC10329682
doi:
Substances chimiques
SS-A antigen
0
Transcription Factors
0
Ube2S protein, human
EC 2.3.2.23
Ubiquitin-Conjugating Enzymes
EC 2.3.2.23
Ribonucleoproteins
0
LPP protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
408Informations de copyright
© 2023. The Author(s).
Références
Clin Cancer Res. 2019 Feb 15;25(4):1389-1403
pubmed: 30397178
Immunity. 2016 Jul 19;45(1):15-30
pubmed: 27438764
Eur Urol. 2012 May;61(5):1039-47
pubmed: 22381169
Signal Transduct Target Ther. 2021 Dec 20;6(1):422
pubmed: 34924561
Mol Cancer. 2022 Nov 14;21(1):210
pubmed: 36376892
Signal Transduct Target Ther. 2020 Feb 29;5(1):11
pubmed: 32296023
Cell Death Dis. 2021 Jan 22;12(1):118
pubmed: 33483464
Nucleic Acids Res. 2022 Feb 22;50(3):1517-1530
pubmed: 35048968
J Exp Clin Cancer Res. 2021 Jun 21;40(1):203
pubmed: 34154613
Elife. 2022 Aug 05;11:
pubmed: 35929733
Cancer Sci. 2019 Sep;110(9):2822-2833
pubmed: 31278883
J Adv Res. 2022 Jul;39:187-202
pubmed: 35777908
Signal Transduct Target Ther. 2021 Feb 16;6(1):64
pubmed: 33589597
Int J Biol Sci. 2022 May 16;18(8):3528-3543
pubmed: 35637955
J Autoimmun. 2012 Aug;39(1-2):77-82
pubmed: 22402340
Theranostics. 2021 Mar 4;11(10):4809-4824
pubmed: 33754029
Oncogene. 2016 Feb 25;35(8):952-64
pubmed: 26028032
Semin Cell Dev Biol. 2022 Dec;132:146-154
pubmed: 34952788
Oncogene. 2012 Nov 8;31(45):4778-88
pubmed: 22266854
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancer Cell Int. 2021 Jan 6;21(1):25
pubmed: 33407510
Cancer Lett. 2021 Jun 28;508:115-126
pubmed: 33794309
Clin Epigenetics. 2021 Apr 26;13(1):91
pubmed: 33902700
Cell Death Differ. 2021 Feb;28(2):591-605
pubmed: 33432113
Mol Cancer. 2022 Jul 15;21(1):146
pubmed: 35840930
J Clin Invest. 2020 Dec 1;130(12):6278-6289
pubmed: 32817589
Cell Res. 2016 Apr;26(4):399-422
pubmed: 27012465
Drug Resist Updat. 2020 Jan;48:100663
pubmed: 31785545
Mol Ther. 2021 Jan 6;29(1):291-307
pubmed: 32950106
Cancer Lett. 2019 May 1;449:31-44
pubmed: 30742945
Front Immunol. 2022 Sep 09;13:968755
pubmed: 36159815
Cell Death Differ. 2021 Nov;28(11):3077-3091
pubmed: 34017102
Cell Death Dis. 2018 Apr 19;9(5):456
pubmed: 29674637
Cell Death Differ. 2022 Feb;29(2):439-450
pubmed: 34511601
Nat Commun. 2020 Dec 8;11(1):6298
pubmed: 33293516
J Virol. 2018 Jun 29;92(14):
pubmed: 29743353
J Cell Commun Signal. 2018 Mar;12(1):143-156
pubmed: 29027626
Int J Mol Sci. 2021 Oct 14;22(20):
pubmed: 34681726
Int J Mol Sci. 2021 Sep 28;22(19):
pubmed: 34638806
FASEB J. 2020 Apr;34(4):5754-5766
pubmed: 32103545
Cancer Lett. 2021 May 1;505:13-23
pubmed: 33610730
Int J Biol Sci. 2020 Sep 13;16(15):2924-2937
pubmed: 33061806
Trends Cell Biol. 2017 May;27(5):322-339
pubmed: 28188028
Nat Cell Biol. 2016 May 27;18(6):579-86
pubmed: 27230526
J Cell Biol. 2019 Jun 3;218(6):1776-1786
pubmed: 31000580
Annu Rev Biochem. 1998;67:425-79
pubmed: 9759494
Cancer Commun (Lond). 2022 May;42(5):447-470
pubmed: 35434944
Cancer Res. 2023 May 15;83(10):1666-1683
pubmed: 36939377
Mol Ther. 2019 Feb 6;27(2):326-341
pubmed: 30660488